PMID- 20655244
OWN - NLM
STAT- MEDLINE
DCOM- 20110405
LR  - 20220408
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
VI  - 52
IP  - 3
DP  - 2010 Dec
TI  - Urinary parameters predictive of cisplatin-induced acute renal injury in dogs.
PG  - 156-62
LID - 10.1016/j.cyto.2010.06.005 [doi]
AB  - A 28-day study was conducted to evaluate changes in urinary cytokine/chemokine 
      expression levels in dogs with renal injury due to administration of cisplatin. 
      Animals (n=17) were administered cisplatin at 0.75 mg/kg/day (i.v.) for five 
      consecutive days. Urine/serum were collected at pre-dosing, 4h post-dosing and on 
      days 2, 3, 4, 8, 10, 14, 16, 18, 21, 23, 25, 28 and unscheduled terminations. 
      Animals were euthanized when serum creatinine (sCr) levels measured at >/= 1.9 
      mg/dL, indicating significant loss of renal function (decreased glomerular 
      filtration rate). Relevant clinical observations included lethargy and 
      dehydration. Pre-study sCr levels ranged from 0.6 to 0.8 mg/dL; on days 1 through 
      4, sCr levels ranged from 0.5 and 1.1mg/dL; and terminal sCr levels ranged from 
      0.6 and 6.6 mg/dL. Histologically, cisplatin-related renal changes were 
      characterized as proximal tubule dilatation, vacuolization, degeneration, 
      regeneration, and interstitial inflammation. Increased interleukin (IL)-2, IL-8, 
      monocyte chemoattractant protein-1 (MCP-1), granulocyte-macrophage 
      colony-stimulating factor (GMCSF) and keratinocyte-derived chemokine (KC) 
      occurred on days 3 through 4. Increased IL-7 occurred on day 4. This study showed 
      for the first time that inflammatory cytokines/chemokines in urine positively 
      identified acute renal tubular injury in dogs at time points earlier than sCr, a 
      traditional marker of nephrotoxicity.
CI  - Copyright (c) 2010 Elsevier Ltd. All rights reserved.
FAU - McDuffie, J Eric
AU  - McDuffie JE
AD  - Global Preclinical Development, Johnson & Johnson Pharmaceutical Research and 
      Development LLC, 3210 Merryfield Row, San Diego, CA 92121, USA. 
      jmcduffi@its.jnj.com
FAU - Sablad, Marciano
AU  - Sablad M
FAU - Ma, JingYing
AU  - Ma J
FAU - Snook, Sandra
AU  - Snook S
LA  - eng
PT  - Journal Article
DEP - 20100723
PL  - England
TA  - Cytokine
JT  - Cytokine
JID - 9005353
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Cytokines)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Acute Kidney Injury/*chemically induced/physiopathology/urine
MH  - Animals
MH  - Antineoplastic Agents/*toxicity
MH  - Cisplatin/*toxicity
MH  - Cytokines/blood/urine
MH  - Dogs
MH  - Glomerular Filtration Rate
MH  - Male
EDAT- 2010/07/27 06:00
MHDA- 2011/04/06 06:00
CRDT- 2010/07/27 06:00
PHST- 2009/08/27 00:00 [received]
PHST- 2010/02/15 00:00 [revised]
PHST- 2010/06/02 00:00 [accepted]
PHST- 2010/07/27 06:00 [entrez]
PHST- 2010/07/27 06:00 [pubmed]
PHST- 2011/04/06 06:00 [medline]
AID - S1043-4666(10)00155-9 [pii]
AID - 10.1016/j.cyto.2010.06.005 [doi]
PST - ppublish
SO  - Cytokine. 2010 Dec;52(3):156-62. doi: 10.1016/j.cyto.2010.06.005. Epub 2010 Jul 
      23.